Project description
Advancing the European approach to medicine
The underlying mechanisms of many complex diseases, such as cancer and neurodegenerative diseases, have not been fully elucidated. Therefore, there is a need for integrated research into chronic, incurable diseases. The EU-funded LifeTime initiative will establish a network for developing, integrating and applying several disruptive technologies to advance our understanding of disease. The consortium will comprise more than 100 research institutions who will work on single-cell analysis, advanced imaging, organoid models of disease and artificial intelligence. Collectively, their work and innovations on our genome's activity in individual cells as they progress through time (ageing or disease) are expected to redefine diagnosis and pathology. They will also advance biomedical and clinical practice, directly benefiting European patients.
Objective
"Understanding how genomes function within cells, and how cells form tissues and dynamically remodel their activities when tissues progress towards disease is among the grand science and technology challenges of our era. The early detection and interception of chronic and progressive diseases would alleviate enormous suffering and a heavy, growing burden on our economy and ageing society. LifeTime aims to revolutionize healthcare by developing and integrating several emerging, disruptive technologies (single-cell multi-omics, advanced imaging, machine learning/artificial intelligence (AI), organoids, and CRISPR-Cas). LifeTime technologies will track and decipher the activity of our genomes (our ""book of life"") in individual cells as they progress through time (ageing or disease)-""LifeTime"". LifeTime's unifying goal is to quantify, model, and predict cell trajectories in tissues and whole organisms. Its long-term vision is that LifeTime technologies will inform the physician about the molecular history of a patient's tissues, their future, and the consequences of perturbations or medical treatments, leading to early diagnosis and effective interception of disease. LifeTime scientists are world-leaders in the required technologies and are committed to establishing an open and dynamic network. LifeTime's focus on developing, integrating and applying several disruptive technologies will induce long-lasting structural changes in European life sciences and healthcare and establish leadership in AI applications for medicine. Together with many industrial partners, we will develop technologies to redefine diagnosis and pathology, and set new standards for mechanism-based drug discovery and disease management for the 21st century. Such advances and their ensuing medical transformation will significantly impact the health of European citizens and stimulate the economy with tremendous benefit for society as a whole."
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- humanitieshistory and archaeologyhistory
- medical and health sciencesbasic medicinepathology
- natural sciencescomputer and information sciencesartificial intelligencemachine learning
- natural sciencesbiological sciencesgeneticsgenomes
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Funding Scheme
CSA - Coordination and support actionCoordinator
13125 Berlin
Germany
See on map
Participants (19)
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
53127 Bonn
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
85764 Neuherberg
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
69120 Heidelberg
See on map
75231 Paris
See on map
75794 Paris
See on map
1030 Wien
See on map
9052 ZWIJNAARDE - GENT
See on map
4056 BASEL
See on map
8000 Aarhus C
See on map
69117 Heidelberg
See on map
08003 Barcelona
See on map
115 27 Athina
See on map
7610001 Rehovot
See on map
20122 Milano
See on map
1011 JV AMSTERDAM
See on map
61-704 POZNAN
See on map
400012 Cluj-Napoca
See on map
17177 Stockholm
See on map
CB22 3AT Cambridge
See on map